Andrea Fernanda Guerrero Medrano

Andrea Fernanda Guerrero Medrano

Auto-generated profile, based on publicly available information

Andrea Fernanda Guerrero Medrano

Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, México

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2021 in Archives of Women's Mental Health
Verified
Journal Article
Closed access
PDF file
JMJuan Manuel Millan-Alanis
Juan Manuel Millan-Alanis
FCFarid Carranza-Navarro
Farid Carranza-Navarro
HLHumberto de León-Gutiérrez
Humberto de León-Gutiérrez
PLPaloma C. Leyva-Camacho
Paloma C. Leyva-Camacho
AGAndrea Fernanda Guerrero-Medrano
Andrea Fernanda Guerrero-Medrano
ESErasmo Saucedo-Uribe
Erasmo Saucedo-Uribe

24 December 2025 in Salud mental
Verified
Journal Article
Open access
YFYvonne Flores-Medina
Yvonne Flores-Medina
MVMauricio Rosel Vales
Mauricio Rosel Vales
RORaul Ivan Escamilla Orozco
Raul Ivan Escamilla Orozco
RSRICARDO ARTURO SARACCO-ALVAREZ
RICARDO ARTURO SARACCO-ALVAREZ
AMAndrea Fernanda Guerrero Medrano
Andrea Fernanda Guerrero Medrano
NMNora Angélica Martínez-Vélez
Nora Angélica Martínez-Vélez
Introduction: Schizophrenia is a chronic, complex, and multifactorial psychiatric disorder characterized by various clinical manifestations. The first line of treatment for this condition is antipsychotics. Second-generation antipsychotics use partial agonist mechanisms of D2 receptors that regulate dopaminergic tone, presumably reducing the incidence of extrapyramidal symptoms. Two second-generation molecules that have shown adequate efficacy for the treatment of positive symptoms in schizophrenia are aripiprazole and brexpiprazole and there are reviews comparing their effectiveness and safety in treatments of up to four weeks. Objective: To evaluate the efficacy and tolerability of aripiprazole compared with brexpiprazole in people diagnosed with schizophrenia or schizophrenia-like psychosis in medium- and long-term treatments. Method: The search was conducted by a specialist from the Cochrane schizophrenia group on March 9, 2023, in the MEERKAT registry, for (*Aripiprazole* and *Brexpiprazole*). Results: A total of 166 registers were identified from the electronic searches. Fifteen were eliminated due to duplication. The titles and abstracts of 151 records were examined, and four full texts were retrieved and assessed for eligibility according to inclusion and exclusion criteria. During this process, three studies were excluded, and finally only one study met the criteria for inclusion in this review. Discussion and conclusion: A single study was found to show data on efficacy, safety, and tolerability in patients with medium-term treatments. Since the evidence identified contains significant biases, it is not possible to establish a recommendation favoring the prescription of one of the antipsychotics in the study over the other.